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Abstract
Background: HSV-tk/ ganciclovir (GCV) gene therapy has been extensively studied in the setting
of brain tumors and largely relies on the bystander effect. Large studies have however failed to
demonstrate any significant benefit of this strategy in the treatment of human brain tumors. Since
dexamethasone is a frequently used symptomatic treatment for malignant gliomas, its interaction
with the bystander effect and the overall efficacy of HSV-TK gene therapy ought to be assessed.
Methods: Stable clones of TK-expressing U87, C6 and LN18 cells were generated and their
bystander effect on wild type cells was assessed. The effects of dexamethasone on cell proliferation
and sensitivity to ganciclovir were assessed with a thymidine incorporation assay and a MTT test.
Gap junction mediated intercellular communication was assessed with microinjections and FACS
analysis of calcein transfer. The effect of dexamethasone treatment on the sensitivity of TK-
expressing to FAS-dependent apoptosis in the presence or absence of ganciclovir was assessed with
an MTT test. Western blot was used to evidence the effect of dexamethasone on the expression
of Cx43, CD95, CIAP2 and BclXL.
Results: Dexamethasone significantly reduced the bystander effect in TK-expressing C6, LN18 and
U87 cells. This inhibition results from a reduction of the gap junction mediated intercellular
communication of these cells (GJIC), from an inhibition of their growth and thymidine
incorporation and from a modulation of the apoptotic cascade.
Conclusion: The overall efficacy of HSV-TK gene therapy is adversely affected by dexamethasone
co-treatment in vitro. Future HSV-tk/ GCV gene therapy clinical protocols for gliomas should
address this interference of corticosteroid treatment.
Background
Herpes Simplex virus thymidine kinase gene (HSV-tk) sui-
cide gene therapy has lately been used in a variety of can-
cer models to sensitize replicating cells to the antiviral
drug ganciclovir (GCV) [1-3]. In this paradigm, tumor
cells transfected with the HSV-tk  gene become able to
Published: 02 April 2005
BMC Cancer 2005, 5:32 doi:10.1186/1471-2407-5-32
Received: 05 September 2004
Accepted: 02 April 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/32
© 2005 Robe et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
Page 2 of 11
(page number not for citation purposes)
mono-phosphorylate ganciclovir, a nucleotide analog.
Ganciclovir monophosphate is subsequently bis and tri-
phosphorylated by cellular kinases and is then incorpo-
rated in the DNA of replicating cells, blocking the cell
cycle and inducing apoptosis [1,4,5]. Cells that are trans-
fected and exposed to ganciclovir can also kill adjacent,
untransfected cells by the so-called bystander effect. In
most tumor types, the bystander effect relies on the trans-
fer of phosphorylated ganciclovir molecules between cells
via their gap junctions [6,7], although other mechanisms
have been described in some models [8-11].
Given their resistance to conventional treatments and
their confinement to the brain, malignant gliomas have
undergone a variety of human trials of HSV-tk gene ther-
apy. The initial enthusiasm has however declined as a
large, multicenter phase 3 clinical study failed to demon-
strate any survival benefit for patients treated with HSV-
TK gene therapy [12]. Efforts are now directed at improv-
ing the protocols, especially by modifying the vectors of
gene distribution in tumor cells [13], the antiviral drugs
[14] and the bystander effect [15-17]. A few papers have
also pointed out that some concomitant treatments
reduce the benefit of HSV-tk/ ganciclovir gene therapy
[18]. In this view, and given the widespread use of corti-
costeroids in the symptomatic treatment of malignant gli-
omas patients, we have assessed the effect of
dexamethasone on the bystander effect in this type of
cancer.
Methods
Cells and culture conditions
Rat C6 malignant glioma cells (ATCC # CCL-107) were
grown in Dulbecco's modification of Eagle's medium sup-
plemented with 3% fetal bovine serum and penicillin
(DEM-3%FBS). C6-TK cells were obtained as described
previously [16] and maintained in DEM-3% FBS supple-
mented with 500 µM geneticin. Human U87 (ATCC #
HTB-14) and LN18 cells (a gift from Prof. N de Tribolet)
were grown in RPMI 1640 medium supplemented with
10% fetal bovine serum and penicillin (RPMI-10%FBS).
U87-TK and LN18-TK cells were obtained as for C6-TK
cells [17] and kept in RPMI-10% FBS supplemented with
500 µM geneticin.
Gap junction intercellular communication
Cells grown for 48 hours in the presence or absence of
dexamethasone were loaded either with CMTMR, a gap-
junction impermeant dye or with calcein, which diffuses
freely through gap junctions. Cells were then mixed for 4
hours, and the percentage of CMTMR-tagged cells having
incorporated calcein after this period – a direct correlate of
GJIC- was determined by FACS analysis of 10,000 cells
[17]. For microinjection experiments, cells were grown on
polyornithine-coated glass coverslips to confluence and
then treated or not with dexamethasone (10-6 M) for 24
hours. The coverslips were then placed in the culture
chamber of a Zeiss® fluorescence microscope perfusion
chamber of a dedicated Zeiss fluorescence microscope,
bathed with EA01 buffer (NaCl 137 mM, KCl 5.7 mM,
CaCl2 1.8 mM, D-Glucose 22.2 mM, Hepes 10 mM), and
injected with a solution of Lucifer Yellow for 30 seconds
as previously described [16]. The number of dye-colored
cells was then counted one minute after the end of the
injection.
Western blots
Western blots were performed as previously described
[17]. Rabbit polyclonal antibodies to connexin 43
(Zymed, San Francisco, CA), CIAP-2, BCLXL and FAS/
CD95 (Santa Cruz Biotechnologies, Heidelberg, Ger-
many) were employed for antigen detection while mono-
clonal antibodies to tubulin (Santa Cruz) or actin (Roche,
Mannheim, Germany) were used to assess loading homo-
geneity. Immunodetection was carried with HRP-coupled
secondary antibodies to mouse (Sigma-Aldrich, Bornem,
Belgium) or rabbit (Amersham, Uppsala, Sweden) anti-
bodies and a chemoluminescent peroxidase substrate
(Pierce, Rockford, IL).
Assessment of the bystander effect
Given proportions of TK- and TK+ cells were seeded in 96-
wells plates at a final density of 10,000 cells/well and
grown for five days in the presence or absence of ganciclo-
vir (2 – 10 µM) and/or dexamethasone (1 µM). Media
were replaced every 48 hours. Cell survival was then
assessed with a 3(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium (MTT) test as described previously [16].
With this test, the cellular viability in each well is directly
correlated to its optical density measured at a wavelength
of 650 nm (OD650). Results are expressed as the ratio of
the OD650 of ganciclovir-treated cells to that of untreated
control wells (set as 100 %). Experiments were run 3 times
in triplicate in the presence or the absence of dexametha-
sone, and results are given as mean ± SD for each
condition.
Sensitivity of TK+ cells to GCV
C6-TK5 cells were seeded in duplicate in 24-wells plates at
a density of 100,000/well and grown for 5 days in the
presence of increasing concentrations of ganciclovir. They
were then harvested and counted on a hemocytometer
using the trypan blue exclusion test. Experiments were run
three times. Results are shown as the percentage (± SD) of
live cells with respect to live cells in control, untreated
wells. For U87-TK and LN18-TK cells, the sensitivity of
cells to GCV (10 µM) after 5 days in culture was assessed
in the presence or absence of dexamethasone (1 µM) with
a MTT test (see previous paragraph for details).BMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
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Cell growth and survival
C6, LN18 and U87 cells were grown for 5 days in the pres-
ence or absence of dexamethasone and cell viability was
assessed with a MTT test. For thymidine incorporation
experiments, C6, LN18 and U87 cells were grown in trip-
licate in 24-wells plates in culture medium supplemented
3H-thymidine (4 µCi/ml, Pharmacia-Amersham, Rosend-
aal, The Nederlands) for 48 hours. The incorporation was
stopped after several PBS washes by digestion of the cells
in 1 ml of 0.1 N NaOH, and 3H-thymidine activity was
recorded with a Wallac® 1400 scintillation counter. Results
were normalized with respect to the protein content of
each culture well as assessed with the method of Bradford
[19]. Results are shown as the mean of 3 independent
experiments ± SD.
CD95-induced cell death
100,000 cells were seeded in triplicate in 96-wells culture
plates and cultured for 24 hours in the presence of soluble
FAS-Ligand (sFAS-L, 2 ng/ml, Alexis, Lausen, Switzer-
land), dexamethasone (1 µM), ganciclovir (10 µM) and of
a combination of these drugs. Cell viability was then
assessed with an MTT test. Experiments were run three
times in triplicate. Results are expressed as the ratio of cell
viability in treated wells to that in untreated wells, ± SD.
Statistical analysis
Statistical analyses were performed as stated in the
'Results' section with the Statview software version 5.0
(SAS Institute, Cary, NC).
Results
Dexamethasone decreases the bystander effect in C6, 
LN18 and U87 cells
C6 cells were mixed with 5 or 10 % of C6-TK cells, and
treated with GCV (2 µM). In the absence of dexametha-
sone (DEX-), the overall cell viability after 5 days in cul-
ture was respectively 20.7 ± 9.3 % and 31.5 ± 10.4 % of
that of controls. It increased to 41.7 ± 12.3 % and 63.8 ±
20.6 % respectively in the presence of 1 µM dexametha-
sone (DEX+, p < 0.05, Student's t-test, Figure 1A). For
LN18 cells grown in the presence of 20% LN18-TK cells
and treated with 10 µM GCV, the overall survival of DEX-
cells was 37.94 ± 6.37 % of that of controls but increased
to 61.93 ± 12.19 % in DEX+ wells (p < 0.05, Student's t-
test, Figure 1B). Similarly, the overall viability of a U87
cells mixed with 10% of U87-TK cells and exposed to 10
µM GCV increased from 45.76 ± 11.1% (DEX-) to 69.16 ±
5.51 % in DEX+ conditions (p < 0.05, Student's t-test, Fig-
ure 1C).
Dexamethasone reduces the gap junction intercellular 
communication (GJIC) of glioma cells
In iontophoresis experiments, Lucifer Yellow dye diffused
to 10.3 ± 10.6 C6 cells (n = 33) per injected cell in control
conditions, and to 7.5 ± 6.5 cells (n = 13) in the presence
of 10-6M of dexamethasone (NS tendency, Student's t-test,
mean ± SD, Figure 2A). In order to assess the GJIC in
much larger cell populations, we analyzed the diffusion of
calcein dye in C6, LN18 and U87 cells by flow cytometry
(FACS). This technique reproducibly demonstrated a
reduction of GJIC following treatment with dexametha-
sone (1 µM). For example, when CMTMR+ C6 cells were
mixed with calcein-loaded, CMTMR- C6 cells, the percent-
age of CMTMR+ cells that incorporated calcein after 4
hours in culture decreased from 15.25 ± 0.911 % in con-
trol conditions (DEX-) to 10.7 ± 1.875 % in the presence
of 1 µM dexamethasone (n = 3, p = 0.0179, Student's t-
test). Using a polyclonal antibody against rat connexin 43,
we did not observe any modulation of the expression and
phosphorylation of Cx43 in C6 cells treated with dexam-
ethasone for 24 hours (Figure 2B). A similar inhibition of
GJIC occurred in LN18 and U87 cells treated with 1 µM
dexamethasone for 24 hours (Figure 2C). LN18 and U87
cells respectively exhibited a very low and high level of
GJIC in control conditions (Figure 2C).
Dexamethasone reduces the sensitivity of TK+ cells to 
ganciclovir
The curve that represents the survival of C6-TK cells
exposed to increasing concentrations of ganciclovir for 5
days was significantly shifted to the right in the presence
of 1 µM dexamethasone (p < 0.05, multiple ANOVA, Fig-
ure 3). Similarly, the viability of LN-TK and U87-TK cells
treated with 10 µM GCV for 5 days increased 2.35-fold
and 1.47-fold respectively in DEX+ conditions as com-
pared with DEX- conditions (n = 3, p < 0.05, Student t-
test). The viability of wild-type C6, U87 and LN18 cells
remained unaffected by ganciclovir (data not shown).
Dexamethasone alters glioma cells proliferation
The viability of wild-type C6, U87 and LN18 cells after 5
days in culture (logarithmic growth phase) was reduced
by respectively 46.75 ± 9.3 %, 33.1 ± 13.25 % and 20.6 ±
7.6 % in the presence of DEX (n = 3 for each condition, p
< 0.005 each, One sample t-test, Figure 4A). DEX also
decreased the incorporation of 3H-thymidine in C6, U87
and LN18 cells by 21.9 ± 8.4 %, 30.7 ± 11 % and 28.5 ±
6.3% respectively (n= 3 for each condition, p < 0.05 each,
Student's t-test, Figure 4B).
Dexamethasone alters CD95-triggered apoptosis in glioma 
cells
GCV (10 µM) significantly sensitized LN-TK and C6-TK
cells but not U87-TK cells to the toxic action of soluble
FAS-L (sFAS-L, 2 ng/ml). This effect was abolished by DEX
(Figure 5A and 5B, and data not shown). Dexamethasone
(1 µM × 24 hours) did not alter the expression of FAS/
CD95 and of the apoptosis inhibitor CIAP-2 in LN18, C6
and U87 cells with these cells, as evidenced by WesternBMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
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Effect of dexamethasone on the bystander effect Figure 1
Effect of dexamethasone on the bystander effect. (A) The viability of C6 cells mixed with 10 % (left) or 5 % (right) of 
C6-TK cells and treated with ganciclovir (2 µM) for 5 days is shown in the presence (+) or absence (-) of dexamethasone (1 
µM, DEX). (B) Viability of LN18 cells mixed with 20 % LN18-TK cells and grown for 5 days with ganciclovir (10 µM) in the 
presence (+) or absence (-) of DEX. (C) Viability of U87 cells mixed with 10 % U87-TK cells and grown for 5 days with ganci-
clovir (10 µM) in the presence (+) or absence (-) of DEX. For each condition, the viability in the absence of ganciclovir was set 
as 100 percents. (*: P < 0.05, Student's t-test)BMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
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Effect of dexamethasone on gap junction intercellular communication Figure 2
Effect of dexamethasone on gap junction intercellular communication. (A) Appearance of confluent cultures of C6 
cells after iontophoresis of Lucifer Yellow in one single cell (*) in the absence (left) or presence (right) of dexamethasone 
(DEX). Photomicrographs are representative of the typical appearance of such injected cells. (B) FACS analysis of calcein dye 
transfer between rat C6 cells in the presence (right) or absence (left) of DEX. The GJIC is directly correlated with the percent-
age of CMTMR+/Calcein+ cells (upper right quadrants, see text for details). This experiment is representative of 3 independent 
experiments each performed on 10,000 cells. A Western blot of Cx43 in C6 cells is shown (left: control conditions, right, DEX 
treatment. See text for details) (C) FACS analysis of calcein dye transfer between human U87 (above) and LN18 (below) cells 
in the presence (right) or absence (left) of DEX. The rightmost pictures illustrate the basal GJIC of both cell types in confluent 
cultures after iontophoresis of Lucifer Yellow in a single cell (*, control conditions).BMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
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blot. The expression of the anti-apoptotic protein BCLXL
however slightly but reproducibly increased in C6 and
LN18 cells (Figure 5C).
Discussion
In this study, we assessed the influence of dexamethasone
on the bystander effect of HSV-TK/ ganciclovir gene ther-
apy in gliomas. Dexamethasone is indeed commonly
used for the symptomatic treatment of brain tumor
patients, and the bystander effect is considered a major
contributor to the efficacy of type of suicide gene therapy
[20,21].
We found that a concentration of 1 µM, i.e. within its ther-
apeutic range [22], dexamethasone significantly inhibited
the bystander effect on C6, LN18 and U87 glioma cells co-
cultured with small proportions (5–20 %) of C6-TK,
LN18-TK and U87-TK cells. This finding is important,
since 10 % of TK-expressing cells represent the threshold
at which C6 tumors can be cured by HSV-TK suicide gene
therapy [2] and since usually less than 5 % of cells are
transfected in vivo with currently available vectors [12,13].
The in vitro bystander effect in glioma cells depends on the
transfer of phosphorylated ganciclovir molecules trough
gap junctions [23,7]. Dexamethasone at 10-6 M moder-
ately but significantly reduced the GJIC of C6, U87 and
LN18 cells, which is a know mechanism through which
drugs decrease the bystander effect [16]. This moderate
reduction of GJIC by DEX in cells that exhibit a low
(LN18), medium (C6) and high (U87) level of GJIC [17]
and originate from humans and a rodent, is consistent
with previously published results [24]. This modulation
of GJIC in C6 cells did not appear to result from a reduced
expression or a differential phosphorylation of connexin
43, the major connexin protein of malignant astroglial
cell [25,26]. We cannot exclude that some Cx43 phospho-
rylation changes were not evidenced with the antibody we
used. It is also possible that the effect of DEX results from
a modification of cell adhesion molecules or other
Sensitivity of C6-TK cells to ganciclovir Figure 3
Sensitivity of C6-TK cells to ganciclovir. The sensitivity of C6-TK cells is shown in control conditions (▲ ) and in response 
to treatment with 1 µM dexamethasone (■ ). Results are expressed as the percentage of living cells in treated conditions at var-
ious concentrations of ganciclovir with respect to ganciclovir-free cultures, and are shown as the mean of 3 independent 
experiments.BMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
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Cell growth and thymidine incorporation Figure 4
Cell growth and thymidine incorporation. (A) The total viability of LN18, U87 and C6 cells grown for 5 days with 1 µM 
dexamethasone (DEX) was determined by way of an MTT test. For each condition, the viability in the absence of DEX was set 
as 100 percents (n = 3, mean ± SD). (B) The incorporation of 3H-thymidine in LN18, U87 and C6 cells grown for 48 hours in 
the presence of DEX is shown (n = 3, mean ± SD). For each condition, the incorporation in the absence of DEX was set as 100 
percents. (*: P < 0.05; ** P < 0.005, Student's t-test).BMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
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Effect of dexamethasone on FAS/CD95-triggered apoptosis Figure 5
Effect of dexamethasone on FAS/CD95-triggered apoptosis. (A) Viability of C6-TK cells after 24 hours of growth in 
the presence of GCV, sFAS-L, sFAS-L + GCV and DEX + sFAS-L + GCV, assessed with a MTT test. This viability was signifi-
cantly altered in cells treated with sFAS-L and GCV and this sensitization was abolished by DEX. (B) Viability of LN18-TK cells 
after 24 hours of growth in the presence of GCV, sFAS-L, sFAS-L + GCV and DEX + sFAS-L + GCV. This viability was signifi-
cantly altered in cells treated with sFAS-L and GCV and this effect was abolished by DEX. For both cell types, the viability in 
the absence of any drug was set as 100 percents. (*: P < 0.05, ANOVA). (C) Western blot analysis of the expression of CIAP-
2, FAS/CD95 and BCLXL in C6, LN18 and U87 cells following treatment with DEX (1 µM).BMC Cancer 2005, 5:32 http://www.biomedcentral.com/1471-2407/5/32
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connexin-interacting proteins as has been suggested for
other effectors [27,28].
It also inhibited by 23–53 % the log-phase growth of all
three types of glioma cells after 5 days in culture, as well
as their incorporation of 3H-thymidine. Of note, dexame-
thasone has also been shown to decrease glioma size in
humans in vivo, an effect that is well-known to clinicians
but is usually transient and lasts for a few weeks only [29].
Since the incorporation of the nucleotide analogue tri-
phosphoganciclovir in replicating DNA strands is
required for its toxicity both in TK-expressing and
bystander cells, this anti-proliferative effect of dexametha-
sone may contribute to its inhibition of the bystander
effect. Such a mechanism has been described for another
inhibitor of DNA replication, Ara-C, that reduces the
bystander effect without altering the GJIC in C6 cells [16].
It is somewhat surprising that dexamethasone decreased
both cell proliferation and GJIC in our experiments. A
decrease of connexin expression and GJIC is indeed usu-
ally associated with an enhanced proliferation of tumor
cells [30,18]. We however did not observe any dexameth-
asone-induced alteration of Cx43 expression on our West-
ern blots, and the enhancement of GJIC by itself is less
likely to control the growth of tumor cells than is the
expression of connexin proteins [31,25]. Finally, gluco-
corticoids are also known to alter cell proliferation via
GJIC-independent mechanisms such as cell cycle block-
ade [32] and alter the PI3K-Akt pathway [33].
GCV treatment has been shown to induce apotosis in TK-
expressing and bystander cells, an effect that notably
implies both ligand-dependent and independent CD95
receptor activation [34-36]. We found that ganciclovir
indeed sensitized C6-TK and LN18-TK cells to the lethal
action of soluble sFAS-L, and this effect was abolished by
dexamethasone. This drug did neither reduce the expres-
sion of FAS/CD95 protein expression nor induce that of
apoptosis inhibitor CIAP-2 in our hands. This latter result
contrasts with the findings of Webster et al. who observed
an induction of CIAP-2 by dexamethasone [37]. We how-
ever observed an enhanced expression of BCLXL, a known
modulator of FAS-dependent apoptosis [38] by dexame-
thasone in our three glioma cell lines, as also described by
Gorman et al. [39].
The reasons why ganciclovir failed to enhance the toxicity
of sFAS-L on U87-TK cells remain unknown and are
beyond the scope of the present work, as is the thorough
assessment of the effects of dexamethasone on HSV-TK/
GCV-induced apoptosis. Our results nevertheless demon-
strate that dexamethasone reduces the bystander effect of
HSV-TK/ ganciclovir gene therapy via at least three differ-
ent mechanisms in rodent and human gliomas in vitro,
i.e. a modulation of GJIC, thymidine incorporation and
apoptotic pathways.
The in vivo significance of our results must also still be val-
idated. Indeed, although the effects of dexamethasone on
HSV-tk gene therapy have partially been studied in vivo on
the 9L animal model of glioma [40,41], none of these
studies specifically addressed the bystander effect. In one
of these studies however [40], dexamethasone tended to
reduce the survival of animals inoculated with TK-express-
ing 9L cells and treated with ganciclovir. Despite a small
number of animals in the GCV (n = 9) and in the GCV +
dexamethasone (n = 10) treatment arms, and although
most of the observations in the control group were cen-
sored, this difference almost reached significance (cited P
= 0.057). In this study, only 10 % of the animals treated
with dexamethasone + GCV remained alive 60 days after
tumor implantation (termination of the observation
period) versus 55 % of the animals treated with GCV
alone, a result that is consistent with our in vitro data.
Given the fundamental role of the bystander effect in clin-
ical situations [12], and since the ultimate evaluation of
the effects of dexamethasone on the bystander effect will
eventually depend on human clinical trials, the design of
upcoming protocols should carefully address this poten-
tial drug interaction.
Conclusion
The overall efficacy of HSV-TK gene therapy is adversely
affected by dexamethasone co-treatment in vitro through a
modulation of apoptosis and gap junction intercellular
communication. Although additional in vivo research is
necesseray to confirm this finding, future HSV-tk/ GCV
gene therapy clinical protocols for gliomas should address
this interference of corticosteroid treatment.
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